Table 4. Utility of LST markers for identification of lymphoid cells in patients with CLPD.
| Marker | Main normal population(s) identifieda | Positive diagnosis | Population subsetting | Diagnostic subclassification | Potential minimal disease value | Prognostic relevance |
|---|---|---|---|---|---|---|
| CD45 | Mature lymphocytes and B-cell precursors | X | X | |||
| CD19 | B-cells, T- and NK-cells by exclusion | X | X | X | ||
| CD20 | B-cells, T- and NK-cells by exclusion | X | X | X | X | |
| SmIgλ and κ | SmIg+ B-cells | X | X | X | ||
| CD38 | Plasma cells and B-cell precursors | X | X | X | X | X |
| SmCD3 | T-cells, B- and NK-cells by exclusion | X | X | X | ||
| CD4 | CD4+ T-cells | X | X | X | X | |
| CD8 | CD8hi T-cells and CD8lo NK-cells | X | X | X | X | |
| CD56 | NK-cells | X | X | X | ||
| TCRγδ | TCRγδ+ T-cells | X | X | X | ||
| CD5 | T-cells | X | X | X |
Abbreviations: CLPD, chronic lymphoproliferative disorders; LST, lymphoid screening tube; Sm, surface membrane.
a
Some markers may be aberrantly expressed in other abnormal lymphoid populations.